Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Third Quarter Trading Update

29 Oct 2025 07:00

RNS Number : 1991F
Elementis PLC
29 October 2025
Β 

29 October 2025

Β 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 of 16 April 2014 which forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

Β 

Elementis plc

Third Quarter Trading Update

Β 

Resilient performance, full year guidance maintained

Β 

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues its scheduled trading update for the three months ended 30 September 2025 ("the quarter").

Despite the ongoing weak market conditions, the Group is on track to deliver full year financial performance in line with market expectations1, supported by our Elevate Elementis strategy and the positive changes being implemented across the Group.

Business performance

The Group delivered a resilient performance in the quarter, with revenue3 of c.$152m, up c.2% compared to the prior period. On a constant currency basis2 revenue was flat reflecting the impact of the weaker dollar.

Adjusted operating profit3 improved against the prior year, driven by self-help and cost-control actions. Year-to-date adjusted operating margins3 are consistent with the H1 performance.

Personal Care sales were flat on constant currency basis with positive price and volume impacts helping to offset the negative impact of mix in the period.

Coatings sales were flat on a constant currency basis due to volume and mix weakness in the Americas. This was offset partially by price improvements. The energy business continues to perform strongly with volumes, pricing and mix higher than the prior year period.

We are on track to deliver $12m in cost savings by end of this year that completes the $30m of cost savings announced in November 2023 for delivery by the end of 2025. In addition, as we drive simplification and agility across the business, we continue to expect around $5m of further savings this year. This is part of the $10m of additional savings to 2026 (net of additional R&D spend) that we announced in July with our Elevate Elementis strategy.

Eaglescliffe

On 14 October 2025, Elementis completed the sale of the disused manufacturing site at Eaglescliffe in the UK to Flacks Group resulting in a cash outflow of c.$11m.Β This follows recently obtained UK Environment Agency consent to the transfer of all operating permits to the buyer. This completes the exit for the Group from the Eaglescliffe site and the removal of c.$20m environmental liabilities from the balance sheet.Β 

Directorate changes

Following the successful completion of several significant milestones for the Group in his time as chair including the sale of the Chromium and Talc businesses, the appointment of Luc van Ravenstein as CEO and the launch of the new Elevate Elementis strategy in July, the Group's Chair, John O'Higgins, has informed the Board that he will not seek re-election at the Company's AGM on 29 April 2026 and will step down as Chair and NED immediately following the AGM. Further details on the Chair succession plan will be provided in due course.

Β 

In recognition of the need to transition to a Board that is more reflective of the reduced size of the business, the Group also announces today that Heejae Chae will be stepping down as NED at the end of this year.

Β 

On 30 September 2025, we announced that Ralph Hewins, CFO, would be retiring from the company after nine years in the role and will step down from his position at the end of 2025. The company also announced that Kath Kearney-Croft, had been appointed to succeed Ralph and will join as CFO designate on 3 November 2025 before becoming CFO and a member of the Elementis Board on 1 January 2026. Kath has been CFO of Learning Technologies Group since 2021, and prior to this has over 20 years of experience in a range of CFO and senior finance roles in the UK and US with SIG plc, The Vitec Group plc, Rexam PLC, and BOC Group.Β 

Β 

Luc van Ravenstein, CEO of Elementis, said:

"I am pleased to report that we have delivered a resilient third quarter performance, despite the continued softness in the coatings markets, demonstrating the strength and quality of our business and our commitment to delivering outstanding value for our customers. While revenue was broadly stable on the prior year period, our margins remain healthy due to the benefits of our proactive operational efficiency initiatives as we create a simpler, leaner Elementis. With market demand in coatings likely to remain soft, we remain focused on executing our Elevate Elementis strategy - designed to accelerate sustainable growth and deliver attractive returns."

Β 

John O'Higgins, Chair of Elementis, said:

"It's been an honour to serve as Chair of Elementis. The Company has navigated significant transformation during this time, and I'm incredibly proud of what we've achieved together in creating a more resilient and focused business. Following the successful completion of several milestones, now is the right time for me to step down and I look forward to continuing to support Luc and the rest of the Board until the next AGM. On behalf of the Board, I would also like to thank Heejae for his valuable contribution to the Board and its Committees during his tenure."

Β 

The person responsible for the release of this announcement on behalf of Elementis plc is Hannah Constantine, Group General Counsel and Company Secretary.

Β 

Enquiries

Investors: Zeeshan Maqbool, Elementis plc Tel: +44 7553 340380

Press: Martin Robinson/Giles Kernick, Teneo Tel: +44 (0) 20 7353 4200

Β 

Β 

Β 

Β Notes:

1. Based on company compiled consensus dated 28 October 2025, the mean adjusted operating profit for the year ended 31 December 2025 is $125m (range $123-127m).

2. Constant currency rates are determined as the reported rates excluding the impact of changes in the average translation exchange rates during the period.

3. Continuing operations basis.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTUWSARVRURUUA
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.